LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces the continuation of its investigation on behalf of Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com.
On April 10, 2019, Helius announced that the U.S. Food and Drug Administration (“FDA”) declined the Company’s request for De Novo classification and 510(k) clearance of the Company’s Portable Neuromodulation Stimulator (PoNS™) device.
On this news, shares of Helius fell nearly 66% on April 10, 2019, thereby injuring investors.
If you purchased Helius securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.